With over $100 million in capital raised from well-heeled investors including Warburg Pincus, the Vertical Group, Norwest Venture Partners, and the Janus Funds, Silk Road Medical is built for the long haul.
The company’s TransCarotid Artery Revascularization (TCAR) procedure promises to upend the treatment of blockages in the carotid artery by changing the direction blood flows through the critical artery, reducing the risk for debris to cause a stroke by reaching the brain.
Under the leadership of Medtech veteran Erica Rogers, Silk Road has secured strong support from clinical, regulatory, and reimbursement communities for its ENROUTE stenting and neuroprotection systems.
Now, the company is setting a clear course toward an IPO, an outcome that would be a welcome win for the Medtech sector.
Read More: https://www.healthegy.com/silk-road-medical-ceo-recalls-vital-lessons-learned/